<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01494298</url>
  </required_header>
  <id_info>
    <org_study_id>H1105110</org_study_id>
    <nct_id>NCT01494298</nct_id>
  </id_info>
  <brief_title>Study of Cholesterol Levels and Types in African Americans With Type 2 Diabetes</brief_title>
  <acronym>LAAD</acronym>
  <official_title>Preliminary Analysis of Lipoprotein Subclasses, Apoprotein Levels, and Genetic Architecture of African-American Males With Type 2 Diabetes. Lipids in African Americans With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mercer University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celera Genomics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mercer University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compared to other races, African-Americans with type 2 diabetes have different cholesterol
      levels, specifically triglycerides and low density lipoprotein. Recent data has shown the not
      only are cholesterol levels important in determining the risk for cardiovascular disease, but
      the size of the cholesterol particles and surface proteins on the cholesterol particles are
      also important. The objective of this study is to determine if African-American males with
      diabetes have different particle size, surface proteins, and cholesterol genetic links than
      African-American male without diabetes and Caucasian-American males with and without
      diabetes.

      African-American males with type 2 diabetes and not taking lipid-lowering medications are the
      current target population.

      After obtaining an informed consent, a complete medical history will be obtained and subjects
      will be examined, noninvasively, for physical signs of elevated cholesterol levels.
      Afterwards, blood samples [one venous puncture, 6 tubes (21 mL total)] will be obtained.
      Blood samples will be coded, sent to Berkeley Heart Lab and/or Clinical Laboratory Services,
      and undergo genetic testing at Mercer University College of Pharmacy and Health Sciences.

      Confidentiality of the subjects will be explained in the consenting process to the subjects.
      All subject samples and information will be coded. Each subject will be given a subject
      number upon consenting and this will be used throughout the study. All pertinent information
      of the subjects will be listed under the designated number, but will not be associated with
      that patient.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ApoB Levels in African American Men With Diabetes and Those Without.</measure>
    <time_frame>At study entry</time_frame>
    <description>Apolipoprotein B Age adjusted least square means are reported because of baseline differences in ages.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LDL Density in African American Males With Diabetes and Those Without Diabetes</measure>
    <time_frame>at entry</time_frame>
    <description>LDL size subclassification was divided into the following groups (from largest size to smallest size): LDL I, LDL IIa, LDL IIb, LDL IIIa, LDL IIIb, LDL IVa, LDL IVa, and LDL IVb.
For differences posted P&lt;0.05 for LDL I, LDL IIb, LDL IIIa, and LDL IIIa +b</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipoprotein a [Lp(a)] in African Americans With Diabetes and Without.</measure>
    <time_frame>at study entry</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">111</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>African American</condition>
  <condition>Cholesterol</condition>
  <condition>Lipoprotein</condition>
  <condition>Apolipoprotein</condition>
  <arm_group>
    <arm_group_label>T2DM</arm_group_label>
    <description>African-American men with type 2 diabetes who are not taking cholesterol-lowering medications.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>African-American men without type 2 diabetes who are not taking cholesterol-lowering medications.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      We will retain a sample of serum, plasma and whole blood.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This is a cross-sectional epidemiologic study in which the lipoprotein subclasses,
        apolipoprotein levels, and genetic polymorphisms of African-American men with type 2
        diabetes will be compared to African-American men without diabetes.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  African American by self-report

          -  Subjects will be defined as having diabetes if they are diagnosed with diabetes per
             the American Diabetes Association guidelines

          -  Subjects without diabetes or impaired glucose tolerance will have a fasting blood
             glucose &lt;100 mg/dL and/or glycosylated hemoglobin(A1C) &lt;6.5%.

        Exclusion Criteria:

          -  Females

          -  Self report of race or ethnicity other than African

          -  Currently taking any lipid-lowering medications
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Grady Health System</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercer Univeristy College of Pharmacy and Health Sciences</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2011</study_first_submitted>
  <study_first_submitted_qc>December 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2011</study_first_posted>
  <results_first_submitted>June 19, 2013</results_first_submitted>
  <results_first_submitted_qc>October 23, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 13, 2013</results_first_posted>
  <last_update_submitted>October 23, 2013</last_update_submitted>
  <last_update_submitted_qc>October 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mercer University</investigator_affiliation>
    <investigator_full_name>Gina J. Ryan</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>African American</keyword>
  <keyword>cholesterol</keyword>
  <keyword>lipoprotein</keyword>
  <keyword>apolipoprotein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Inclusion criteria were male gender, African American by self report and not taking of lipid-lowering medications. Subjects with diabetes were recruited from the Grady Diabetes Clinic in Atlanta, Georgia. Control subjects were recruited from the general Metro-Atlanta Area and had to have a fasting blood glucose &lt;100 mg/dL.</recruitment_details>
      <pre_assignment_details>1 subject was excluded from the diabetes group because he had type 1 diabetes
Exclusion from control group 1- was taking lipid lowering medications
1 - was not possible to do venous blood draw 5 - FBG between 100-126 mg/dL 2 - FBG&gt;126 and were reassigned to diabetes group</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>T2DM</title>
          <description>African American men with type 2 diabetes and not taking cholesterol-lowering medications.</description>
        </group>
        <group group_id="P2">
          <title>Controls</title>
          <description>African American men without type 2 diabetes and not taking cholesterol-lowering medications.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The primary objective of this project was to determine the difference in Apo B levels in African-American men with and without diabetes.To achieve a power of 80%, 48 subjects in each group were needed to detect 15 mg/dL difference in ApoB levels, assuming a standard deviation of 26 mg/dL if alpha was set at 0.05.</population>
      <group_list>
        <group group_id="B1">
          <title>T2DM</title>
          <description>African American Men with Type 2 Diabetes</description>
        </group>
        <group group_id="B2">
          <title>Controls</title>
          <description>African American Men without diabetes</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" spread="8"/>
                    <measurement group_id="B2" value="44.5" spread="13.1"/>
                    <measurement group_id="B3" value="48.5" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>47</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>ApoB Levels in African American Men With Diabetes and Those Without.</title>
        <description>Apolipoprotein B Age adjusted least square means are reported because of baseline differences in ages.</description>
        <time_frame>At study entry</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T2DM</title>
          </group>
          <group group_id="O2">
            <title>Controls</title>
          </group>
        </group_list>
        <measure>
          <title>ApoB Levels in African American Men With Diabetes and Those Without.</title>
          <description>Apolipoprotein B Age adjusted least square means are reported because of baseline differences in ages.</description>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" spread="3"/>
                    <measurement group_id="O2" value="65" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis - There will be differences in ApoB between AA with T2DM and those without. To achieve a power of 80%, 48 subjects in each group were needed to detect 15 mg/dL difference in ApoB levels, assuming a standard deviation of 26 mg/dL if alpha was set at 0.05. Continuous data were compared using a Students t-test and categorical data were compared using test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.002</p_value>
            <p_value_desc>The control group average age was 6 years lower(P=0.001). Results were adjusted via a logistic regression and presented as age-adjusted means and SE. The unadjusted differences had similar results.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDL Density in African American Males With Diabetes and Those Without Diabetes</title>
        <description>LDL size subclassification was divided into the following groups (from largest size to smallest size): LDL I, LDL IIa, LDL IIb, LDL IIIa, LDL IIIb, LDL IVa, LDL IVa, and LDL IVb.
For differences posted P&lt;0.05 for LDL I, LDL IIb, LDL IIIa, and LDL IIIa +b</description>
        <time_frame>at entry</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T2DM</title>
            <description>African-American men with type 2 diabetes who are not taking cholesterol lowering medications</description>
          </group>
          <group group_id="O2">
            <title>Controls</title>
            <description>African-American men without type 2 diabetes who are not taking cholesterol lowering medications</description>
          </group>
        </group_list>
        <measure>
          <title>LDL Density in African American Males With Diabetes and Those Without Diabetes</title>
          <description>LDL size subclassification was divided into the following groups (from largest size to smallest size): LDL I, LDL IIa, LDL IIb, LDL IIIa, LDL IIIb, LDL IVa, LDL IVa, and LDL IVb.
For differences posted P&lt;0.05 for LDL I, LDL IIb, LDL IIIa, and LDL IIIa +b</description>
          <units>percentage of total LDL particles</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LDL I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" spread="1"/>
                    <measurement group_id="O2" value="29" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL IIa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" spread="1"/>
                    <measurement group_id="O2" value="27" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL IIb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" spread="1"/>
                    <measurement group_id="O2" value="24" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL IIIa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" spread="1"/>
                    <measurement group_id="O2" value="13" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL IIIb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.3"/>
                    <measurement group_id="O2" value="3.4" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL IVa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.2"/>
                    <measurement group_id="O2" value="2.8" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL IVb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.1"/>
                    <measurement group_id="O2" value="1.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL IIIa +b</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" spread="2"/>
                    <measurement group_id="O2" value="16" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lipoprotein a [Lp(a)] in African Americans With Diabetes and Without.</title>
        <time_frame>at study entry</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T2DM</title>
          </group>
          <group group_id="O2">
            <title>Controls</title>
          </group>
        </group_list>
        <measure>
          <title>Lipoprotein a [Lp(a)] in African Americans With Diabetes and Without.</title>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" spread="5"/>
                    <measurement group_id="O2" value="45" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.84</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Since this was an observational study, serious and/or other non-serious adverse events were not collected/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>T2DM</title>
          <description>African American men with type 2 diabetes and not taking cholesterol-lowering medications.</description>
        </group>
        <group group_id="E2">
          <title>Controls</title>
          <description>African American men without type 2 diabetes and not taking cholesterol-lowering medications.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gina Ryan Clinical Professor</name_or_title>
      <organization>Mercer University College of Pharmacy</organization>
      <phone>678.547.6222</phone>
      <email>ryan_gj@mercer.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

